5W9E

Toxoplasma Gondii CDPK1 in complex with inhibitor GXJ-186

Summary for 5W9E

• Entry DOI: 10.2210/pdb5w9e/pdb
• Descriptor: Calmodulin-domain protein kinase 1, 1-tert-butyl-3-[(3-chlorophenyl)sulfanyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine (3 entities in total)
• Functional Keywords: cdpk, parasitology, atp-binding, kinase, nucleotide-binding, serine/threonine-protein kinase, transferase, structural genomics, structural genomics consortium, sgc, transferase-transferase inhibitor complex, transferase/transferase inhibitor
• Biological source: Toxoplasma gondii
• Total number of polymer chains: 1
• Total formula weight: 55560.75

Authors

El Bakkouri, M.,Lovato, D.,Loppnau, P.,Lin, Y.H.,Rutaganaria, F.,Lopez, M.S.,Shokat, L.,Bountra, C.,Edwards, A.M.,Arrowsmith, C.H.,Sibley, D.,Hui, R.,Walker, J.R. (deposition date: 2017-06-23, release date: 2017-08-02, Last modification date: 2026-05-20)

Primary citation

Rutaganira, F.U.,Barks, J.,Dhason, M.S.,Wang, Q.,Lopez, M.S.,Long, S.,Radke, J.B.,Jones, N.G.,Maddirala, A.R.,Janetka, J.W.,El Bakkouri, M.,Hui, R.,Shokat, K.M.,Sibley, L.D.
Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii.
J.Med.Chem., 60:9976-9989, 2017

PubMed Abstract: Calcium dependent protein kinase 1 (CDPK1) is an essential enzyme in the opportunistic pathogen Toxoplasma gondii. CDPK1 controls multiple processes that are critical to the intracellular replicative cycle of T. gondii including secretion of adhesins, motility, invasion, and egress. Remarkably, CDPK1 contains a small glycine gatekeeper residue in the ATP binding pocket making it sensitive to ATP-competitive inhibitors with bulky substituents that complement this expanded binding pocket. Here we explored structure-activity relationships of a series of pyrazolopyrimidine inhibitors of CDPK1 with the goal of increasing selectivity over host enzymes, improving antiparasite potency, and improving metabolic stability. The resulting lead compound 24 exhibited excellent enzyme inhibition and selectivity for CDPK1 and potently inhibited parasite growth in vitro. Compound 24 was also effective at treating acute toxoplasmosis in the mouse, reducing dissemination to the central nervous system, and decreasing reactivation of chronic infection in severely immunocompromised mice. These findings provide proof of concept for the development of small molecule inhibitors of CDPK1 for treatment of CNS toxoplasmosis.

PubMed: 28933846
DOI: 10.1021/acs.jmedchem.7b01192

Experimental method

X-RAY DIFFRACTION (2.44 Å)